Tallying Up the Dx Score Card
An overview of the diagnostics industry's year-to-date performance is not inspiring. Total industry sales are expected to be down 2-3% this year from last year, analysts say. The top eight diagnostics companies have an increasing percentage of the business. Hardest hit were immunoassay and clinical chemistry segments; best-performers were nucleic acid probes and diabetes care.
You may also be interested in...
Boston Scientific has agreed to pay $1.07bn to acquire Lumenis’ surgical laser business from Baring Private Equity Asia. See what Meghan Scanlon, president of Boston Scientific’s urology and pelvic health business, said about it here.
US Remains Conservative On Vaccine Dosing Regimens As CDC’s ACIP Highlights Minimal Comfort With Relying On Unproven Correlates
The Center for Disease Control and Prevention’s Advisory Committee on Immunization Practices concerns about making COVID-19 vaccine dose regimen changes based on unproven immune correlates of protection could be a warning sign to sponsors about roadblocks they might face if updating vaccines to address viral variants or conducting pediatric studies relying on such surrogate endpoints.
J&J CEO Gorsky says the agency is working with sponsors to ensure the proper data is gathered to make the vaccine available in children.